21 September 2022 - The Schizophrenia Society of Canada is joined by the schizophrenia community across Canada in its disappointment with ...
20 September 2022 - Novartis Pharmaceuticals Canada and the pan Canadian Pharmaceutical Alliance have successfully concluded negotiations for Luxturna (voretigene neparvovec), ...
6 September 2022 - Six health technology assessment bodies from three continents will join forces to collaborate on a range of ...
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
7 September 2022 - A week after a B.C. family went public with its plea for a life-changing drug for ...
7 September 2022 - The country, with an increasing immunoglobulin usage rate, currently imports about 85% of its immunoglobulin demand for ...
7 September 2022 - Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians ...
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
1 September 2022 - Provincial jurisdictions will make the final decision on public reimbursement. ...
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
29 August 2022 - Evelyn Larson visited a private clinic in Saskatoon only to find the Yukon did cover the treatment ...
18 August 2022 - High demand in the United States for a new weight-loss medication has indefinitely delayed its arrival ...
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
9 August 2022 - CADTH is pleased to announce the introduction of the Real-World Evidence Guidance Working Group. ...
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...